Reportlinker Adds Antifungal Drugs: Technologies and Global Markets

NEW YORK, May 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antifungal Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0196570/Antifungal-Drugs-Technologies-and-Global-Markets.html

THIS REPORT:

An examination of the major markets for antifungal applications in human healthcare, with an extensive review of therapies in human development phases I-III 

Analysis of each market segment on the global level, with data for 2008, estimates for 2009, and 5-year forecasts, with compound annual growth rates (CAGRs), through 2014

Highlights and reviews of FDA restrictions, government legislation, as well as discussions on fungal resistance and changes in consumer preferences, such as a greater demand for OTC medications and/or natural and alternative remedies

Presentation of new drug and patent applications, new methods of drug administration, drug discovery and development, and various clinical trials and applications

Profiles of important companies.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 2

INTENDED AUDIENCE 2

SCOPE OF REPORT 3

METHODOLOGY 3

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 4

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY 5

SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL SALES OF HUMAN ANTIFUNGALS, 2009 AND 2014 ($ MILLIONS) 6

Chapter-3: OVERVIEW

HISTORY AND CURRENT STATE OF ANTIFUNGALS 7

TYPES OF PATHOGENIC FUNGI 8

DEFINITION OF THE INDUSTRY 8

CONCEPTS IN THE INDUSTRY 9

IMPORTANCE OF THE INDUSTRY 9

PRODUCT LIFE CYCLES 10

TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG 11

DEVELOPMENT OF ANTIFUNGALS 11

DEVELOPMENT OF ANTIFUNGALS (CONTINUED) 12

FDA-APPROVED ANTIFUNGALS 13

AZOLE ANTIFUNGALS 13

ECHINOCANDINS 13

POLYENES 14

ALLYLAMINES 14

MISCELLANEOUS ANTIFUNGALS 14

FUTURE DEVELOPMENTS 14

HUMAN CLINICAL DEVELOPMENT, 2007–2009 15

NEW DRUG ACTIVITY 16

TABLE 2 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2007–2009 17

TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2007 AND 2012 17

ACTIVE OR COMPLETED STUDIES POSTED OR UPDATED, 2007-2009 17

TABLE 4   ACTIVE OR COMPLETED STUDIES, 2007-2009 18

TABLE 4 (CONTINUED) 19

TABLE 4 (CONTINUED) 20

Chapter-4: INTRODUCTION TO INDUSTRY APPLICATIONS OF ANTIFUNGAL MEDICINAL THERAPEUTICS

SCOPE OF APPLICATIONS: HUMAN HEALTHCARE 21

HUMAN FUNGAL INFECTIONS 22

RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS 23

TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS 24

TABLE 5 (CONTINUED) 25

FUNGAL SPECIES THAT CAUSE INFECTION IN HUMANS 25

Candidiasis 25

Some Basic Facts about Candida Infections 26

Some Basic Facts … (Continued) 27

Some Basic Facts … (Continued) 28

Cutaneous Candidiasis 29

Chronic Mucocutaneous Candidiasis 29

GI Tract Candidiasis 29

Respiratory Tract Candidiasis 29

Genitourinary Tract Candidiasis 30

Hepatosplenic Candidiasis 30

Systemic Candidiasis 30

Candidemia 30

Disseminated Candidiasis 31

Aspergillosis 32

Blastomycosis 33

Coccidioidomycosis 34

Cryptococcosis 35

Dermatophytosis 36

Dermatophytosis (Continued) 37

Histoplasmosis 38

Onychomycosis 39

Paracoccidioidomycosis 40

Pseudallescheriasis 41

Sporotrichosis 41

Zygomycosis 42

TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES 43

MORE RARE FUNGAL INFECTIONS AND DISORDERS 44

Literature Review 44

FUNGAL DRUG RESISTANCE 45

CURRENT DRUG RESISTANCE TOPICS: A GLOBAL VIEW 46

MDR SPECIES 47

MDR Species (Continued) 48

MDR Species (Continued) 49

Literature Review 50

TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE 51

STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY 51

Literature Review 52

Literature Review (Continued) 53

Chapter-5: HUMAN ANTIFUNGAL AGENTS

TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS) 54

CLASSES OF ANTIFUNGALS 54

ECHINOCANDINS 54

Literature Review 55

AZOLES 55

Literature Review 56

POLYENES 56

Literature Review 56

OTHER 57

TABLE 9 GLOBAL ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS, THROUGH 2014 ($ MILLIONS) 57

TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%) 58

FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS (%) 58

TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE, 2006* 59

TABLE 12 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY 60

TABLE 13 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT 61

SIDE EFFECTS 62

TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS 63

OTC ANTIFUNGAL PREPARATIONS 64

TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION 65

NATURAL ANTIFUNGAL REMEDIES 65

NATURAL ANTIFUNGAL REMEDIES (CONTINUED) 66

TYPES OF NATURAL ANTIFUNGAL REMEDIES 67

Herbal Remedies 67

Enzyme-based Antifungal Agents 68

Enzyme-based Antifungal Agents (Continued) 69

TABLE 16 COMMON NATURAL ANTIFUNGALS 70

SUMMARY OF SELECTED NATURAL ANTIFUNGAL 71

Aloe 71

Literature Review 71

Curcumin 72

Literature Review 73

Mint 73

Literature Review 73

Wild Marjoram 74

Literature Review 74

Radish 75

Literature Review 75

Parnafungins 75

Literature Review 76

Ginseng 77

Literature Review 77

Walnut 77

Literature Review 78

Pau d'arco 78

Literature Review 78

Garlic 78

Literature Review 78

Grapefruit Seed 79

Literature Review 80

Olive Leaf 80

Literature Review 80

Goldenseal 80

Literature Review 81

Oregano 81

Literature Review 81

Tea Tree 82

Literature Review 82

NATURAL REMEDIES IN EARLIER DEVELOPMENT 83

Literature Review 83

Literature Review (Continued) 84

LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS 85

Specimen Examination 85

Cultures 85

Blood Serology 85

ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS 86

CAM Testing and Specialized Laboratories 86

Questionnaire for Symptoms 87

Chapter-6: COMMON ENVIRONMENTAL FUNGI

MOLDS AND THE HUMAN ISSUES THEY PRODUCE 88

WHY ENVIRONMENTAL MOLD IS A UNIQUE PROBLEM 89

HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOLD 90

HEALTH RISKS DUE TO … (CONTINUED) 91

TABLE 17 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS 92

TABLE 18 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOLD REACTIONS 92

TABLE 19 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS 93

ENVIRONMENTAL MOLDS 93

ALTERNARIA 93

Literature Review 94

ASPERGILLUS 95

Literature Review 95

CLADOSPORIUM 96

Literature Review 96

PENICILLIUM 97

Literature Review 98

EUROTIUM 98

Literature Review 99

RHIZOPUS 99

Literature Review 99

MUCOR 100

Literature Review 100

GEOTRICHUM 101

Literature Review 101

FUSARIUM 102

Literature Review 102

STACHYBOTYRS 102

Literature Review 103

WALLEMIA 103

Literature Review 103

TRICHOTHECIUM 104

Literature Review 104

SCOPULARIOPSIS BREVICAULIS 104

Literature Review 104

SCYTALIDIUM DIMIDIATUM 105

Literature Review 105

TRICHODERMA 106

Literature Review 106

PAECILOMYCES VARIOTII 107

Literature Review 107

Literature Review (Continued) 108

Chapter-7: GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS

GOVERNMENT REGULATIONS 109

FDA 109

TABLE 20 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA, 1997–2009 110

TABLE 20 (CONTINUED) 111

TABLE 20 (CONTINUED) 112

TABLE 20 (CONTINUED) 113

TABLE 20 (CONTINUED) 114

TABLE 20 (CONTINUED) 115

TABLE 20 (CONTINUED) 116

EPA 116

EPA (Continued) 117

USDA 118

FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS 118

PROFESSIONAL ASSOCIATIONS 118

MEDICAL AND VETERINARY ASSOCIATIONS 118

AGRICULTURAL ASSOCIATIONS 119

OTHER ENVIRONMENTAL ASSOCIATIONS 119

Chapter-8: ANTIFUNGAL COMPANIES

HUMAN HEALTHCARE 120

PHARMACEUTICAL MANUFACTURERS 120

TABLE 21 MAJOR GLOBAL ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS 121

FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%) 121

FIGURE 2 (CONTINUED) 122

MAJOR PHARMACEUTICAL MANUFACTURER PROFILES 122

TABLE 22 THE TOP 10 SALES VOLUMES OF ALL PHARMACEUTICAL PRODUCTS BY COUNTRY, 2008 ($ MILLIONS/%) 123

FIGURE 3 TOP 10 GROWTH RATES BY COUNTRY, 2008 (%) 123

TABLE 23 THE TOP 5 ANTIFUNGALS PRODUCING COMPANIES IN TERMS OF OVERALL SALES, 2008 124

TABLE 24 MAJOR GLOBAL ANTIFUNGAL SALES FORECAST, THROUGH 2014 ($ MILLIONS) 124

Astellas Pharma, Inc. 124

Bayer HealthCare 125

Enzon Pharmaceuticals 125

Galderma Pharma SA/Galderma SA 126

Gilead Sciences, Inc. 126

Medicis Pharmaceutical Corp. 126

Novartis International AG 127

Pfizer, Inc. 127

Taro Pharmaceutical Industries, Ltd. 128

Taro USA, Inc. 128

Teva Pharmaceutical Industries, Ltd. 128

OTC ANTIFUNGAL MANUFACTURERS 129

PHARMACEUTICAL OTC MARKET 129

TABLE 25 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS 130

MAJOR PHARMACEUTICAL-BASED OTC MANUFACTURER PROFILES 130

Alva-Amco Pharmacal 130

Blaine Labs 130

Dartmouth Pharmaceuticals 131

Del Laboratories 131

Ganeden Biotech 131

Kramer Laboratories 132

Novartis International AG 132

Ortho McNeil 132

PEDiNOL Pharmacal, Inc. 133

Stiefel Laboratories 133

Tarmac Products 133

ALTERNATIVE OTC MANUFACTURERS 134

TABLE 26 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS 134

MAJOR ALTERNATIVE OTC MANUFACTURER PROFILES 134

Aqua Flora 134

Crystal Star Herbal Nutrition 135

Enzymedica 135

Forest Herbs Research 135

Garden of Life 136

Michael's Naturopathic Programs 136

Nature's Plus 137

NOW Foods 137

Nutrition Now 137

ProSymbiotics 138

Pure Essence Laboratories 138

Rainbow Light 139

Renew Life 139

Solaray 139

Vitanica 140

Chapter-9: ANTIFUNGAL INDUSTRY

ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE 141

ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT 141

TABLE 27 NEW PRESCRIPTION ANTIFUNGALS, 2005–2009 142

INCREASED TYPES OF TESTING 143

Need to Increase Use and Acceptance of Newer Drugs 143

SOME GENERAL STATISTICS 144

EXPERIMENTAL RESEARCH: CLINICAL TRIALS PERFORMED AND SELECTED PRECLINICAL AND IN-VITRO STUDIES 145

A GENERAL OVERVIEW OF NON-PHARMACEUTICAL ANTIFUNGAL TECHNOLOGIES 146

Laser and Photodynamic Therapy 146

Studies 147

Literature Review 147

mAbs 148

Diagnostics and Assays 148

Literature Review 149

Computer Modeling Technology 150

Literature Review 150

R&D SECTION: AN OVERVIEW OF NEW COMBINATIONS 150

Excluded Therapies 151

Included Therapies 151

NEW CLINICAL EXPERIMENTAL AND COMBINATION STUDIES, 2007–2009 152

TABLE 28 NEW CLINICAL EXPERIMENTAL AND COMBINATION STUDIES, 2007–2009 153

TABLE 28 (CONTINUED) 154

TABLE 28 (CONTINUED) 155

TABLE 28 (CONTINUED) 156

TABLE 28 (CONTINUED) 157

TABLE 28 (CONTINUED) 158

Human In-vivo Literature Review 158

Human In-vivo … (Continued) 159

Human In-vivo … (Continued) 160

Human In-vivo … (Continued) 161

Preclinical Literature Review 162

Preclinical Literature Review  (Continued) 163

In-vitro Literature Review 164

In-vitro Literature Review (Continued) 165

TRENDS IN CLASS USED AND ADMINISTRATION METHOD 166

TABLE 29 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION (%) 167

FIGURE 4 PHARMACEUTICAL ANTIFUNGALS ROUTE OF ADMINISTRATION (%) 167

TABLE 30 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ROUTE OF ADMINISTRATION, THROUGH 2014 ($ MILLIONS) 168

UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS 168

Shifting Market from Prescription to OTC 168

TABLE 31 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS, 2005 169

TABLE 32 GLOBAL SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 ($ MILLIONS) 169

Market Demand for OTC Products 169

Market Demand for … (Continued) 170

Chapter-10: PATENT ANALYSIS

PURPOSE OF A PATENT ANALYSIS 171

DUE CARE IN REVIEWING THE PATENT ANALYSIS 171

NEW ANTIFUNGAL PATENTS ISSUED 172

TABLE 33 U.S. ANTIFUNGAL PATENT TRENDS, 1990–2009 173

TABLE 34 NEW U.S. ANTIFUNGAL PATENTS ISSUED, 2007–2009 173

TABLE 34 (CONTINUED) 174

TABLE 34 (CONTINUED) 175

TABLE 34 (CONTINUED) 176

TABLE 35 ASSIGNEES OF THREE OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS, 2007–2009 176

TABLE 36 U.S. PATENT TRENDS BY COUNTRY, 2007–2009 (NUMBER/%) 176

TABLE 36 (CONTINUED) 177

FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007–2009   (%) 177

TRENDS IN PATENT APPLICATIONS 177

TABLE 37 U.S. PATENT APPLICATION TRENDS, 2007–2009 178

FIGURE 6 U.S. ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2007–2009 (%) 178

TABLE 38 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007–2009 179

FIGURE 7 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007–2009 (%) 179

TABLE 39 NEW U.S. PATENT APPLICATIONS, 2007–2009 180

TABLE 39 (CONTINUED) 181

TABLE 39 (CONTINUED) 182

TABLE 39 (CONTINUED) 183

TABLE 39 (CONTINUED) 184

TABLE 39 (CONTINUED) 185

TABLE 40 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISM OF ACTION, 2007–2009 186

TABLE 41 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007–2009 186

FIGURE 8 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2007–2009 (%) 187

PATENT EXPIRATIONS 187

TABLE 42 PATENT EXPIRATIONS, 2006–2011 188

APPENDIX 189

TABLE 43 PHARMACEUTICAL COMPANIES 189

TABLE 43 (CONTINUED) 190

TABLE43 (CONTINUED) 191

TABLE 43 (CONTINUED) 192

To order this report:

Drug and Medication Industry: Antifungal Drugs: Technologies and Global Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker